Friday, October 23, 2026
In today's episode, Dr. Alok Patel (@alokpatelmd) & Adam Rose (@adjoro) cover a phase three trial of nicotinamide riboside in early Parkinson disease. Over 52 weeks, the supplement boosted NAD metabolism but showed no clinical benefit, raising questions for NAD boosting strategies. They also walk through a large hospital comparison of phenobarbital and diazepam for alcohol withdrawal, with similar stays and ventilation rates and fewer self directed discharges on phenobarbital, and why diazepam protocols may stay the course pending randomized trials. Plus: they also discuss national measles trends, FDA warning letters to Amazon and Walmart, and more.
New to Medlines? Check out the full playlist: https://www.youtube.com/playlist?list=PLR-tmjMS1yRo
Have a story, think we missed something, want to say hi, or curious to learn about the Medlines team? Visit https://www.medlinespod.com or email medlines@human-content.com.
Sources & Media Attributions for Today's Episode Available At: https://www.medlinespod.com/sources
Medlines is a Human Content Production